Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

The selective 5-HT6 receptor antagonist SLV has putative cognitive- and social interaction enhancing properties in rodent models of cognitive impairment

: Bruin, N.M.W.J. de; Loevezijn, A. van; Wicke, K.M.; Haan, M. de; Venhorst, J.; Lange, J.H.M.; Groote, L. de; Neut, M.A.W. van der; Prickaerts, J.; Andriambeloson, E.; Foley, A.G.; Drimmelen, M. van; Wetering, M. van der; Kruse, C.G.


Neurobiology of learning and memory 133 (2016), pp.100-117
ISSN: 1074-7427
ISSN: 1095-9564
Journal Article
Fraunhofer IME ()

In the present study, our aim was to investigate whether the novel highly selective 5-hydroxytryptamine(6) (5-HT6) receptor antagonist SLV can ameliorate impairments in cognition and social interaction with potential relevance for both schizophrenia and Alzheimer's disease (AD). SLV sub-chronically- treated Wistar rats reared in isolation showed significantly enhanced prepulse inhibition (PPI) and object recognition performance when compared to vehicle - treated rats. In the isolated rats, also a significant reduction in expression of hippocampal neural cell adhesion molecule polysialylation (NCAM-PSA) was found which was ameliorated following treatment with SLV (30 mg/kg). The social engagement deficit in rats exposed in utero (on gestational day 12.5) to valproic acid (VPA) was reversed by treatment with SLV (30 mg/kg). SLV (20 and 30 mg/kg, p.o.) fully reversed MK-801 - induced deficits in the ORT and also scopolamine - induced deficits in both the Object Recognition Task (ORT) and Object Location Task (OLT) in Wistar rats. In addition, a combination of sub-optimal doses of SLV and donepezil attenuated scopolamine-induced ORT deficits. Furthermore, SLV (10 mg/kg, p.o.) reversed spontaneous alternation deficits in the T-maze induced by MK-801 administration in Swiss mice and in aged C57131/6J mice. SLV additionally improved T-Maze spatial learning and passive avoidance learning in Sprague-Dawley rats with amyoid-beta (A beta) injections into the hippocampus. In contrast, no benefits were found with SLV or the tested reference compounds (donepezil and RVT-101) on cognitive performance of 12 months old Tg2576 mice. Also, in the social recognition task, an absence of cognitive enhancing properties was observed with SLV on "normal forgetting" in Wistar rats. Finally, analysis of spontaneous inhibitory postsynaptic currents (sIPSCs) frequency recorded from pyramidal cells revealed a reduction in the presence of 1 mu M of SLV. In conclusion, SLV was investigated in several rodent animal models and found to be effective at a least effective dose (LED) of 20 mg/kg and 10 mg/kg (p.o.) in the rat and the mouse, respectively. (C) 2016 Elsevier Inc. All rights reserved.